Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT07073937

Three Year Outcomes of Combined Hydrus Microstent With iTrack Canaloplasty

Status
Enrolling By Invitation
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
University of Utah · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of this study is to learn if combining minimally invasive glaucoma surgery (MIGS) procedures with different mechanisms of action increases the effectiveness of MIGS. The main question the study aims to answer is: Does combining viscodilation (a surgical technique, often used in glaucoma treatment, that involves using a high-viscosity, elastic gel to widen and open the Schlemm's canal, a main drainage channel in the eye) with the iTrack catheter, along with the Hydrus microstent, show better reduction in intraocular pressure than cataract surgery alone? Researchers will retrospectively review charts of patients who have open-angle glaucoma who have undergone combination Hydrus implantation and 360-degree iTrack canaloplasty with concomitant cataract surgery, who have at least 36 months of clinical follow-up data. Baseline demographic information and severity of glaucoma will be recorded, as will change from baseline yearly to three years in average optical coherence tomography (OCT) retina nerve fiber layer (RNFL) measurements and visual field (VF) pattern standard deviation. Safety outcomes and the percentage of eyes requiring secondary surgical intervention will be recorded at yearly time points.

Conditions

Interventions

TypeNameDescription
OTHERRetrospective chart reviewRetrospective study; a total of approximately 100 subjects have been identified to have had minimum 36 months follow-up.

Timeline

Start date
2025-08-01
Primary completion
2026-09-17
Completion
2026-11-04
First posted
2025-07-20
Last updated
2026-01-09

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT07073937. Inclusion in this directory is not an endorsement.